---
title: 'RAD51 testing in patients with early HER2-negative breast cancer and homologous
  recombination deficiency: post-hoc analysis of the GeparOla trial'
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39786436/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250109170938&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In a pre-selected population with HRD according to a genetic
  test, RAD51 testing identifies patients with different pCR rates under PARPi or
  platinum-based therapies. Future biomarker-driven studies should consider this information
  to refine stratification factors and to improve patient ...'
disable_comments: true
---
CONCLUSIONS: In a pre-selected population with HRD according to a genetic test, RAD51 testing identifies patients with different pCR rates under PARPi or platinum-based therapies. Future biomarker-driven studies should consider this information to refine stratification factors and to improve patient ...